The Medicines Co.’s Cangrelor’s Full CHAMPION PHOENIX Results Bode Well For Filing
This article was originally published in Pharmaceutical Approvals Monthly
After two failed studies, The Medicines Co.’s rapid-acting I.V. antiplatelet drug reduces events by more than 20% in the Phase III CHAMPION PHOENIX angioplasty trial against Plavix. However, the company is already facing demand for studies against the newer and more potent antiplatelet drugs Brilinta and Effient.